J3396 HCPCS Level II code: Injection, verteporfin, 0.1 mg
J3396 is the HCPCS code for “Injection, verteporfin, 0.1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3396Injection, verteporfin, 0.1 mg
Short description: Verteporfin injection
HCPCS · United States
Medicare details
The indicators CMS publishes with J3396 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Other medical items or services
- BETOS category
- Other drugs
- Added
- Jan 1, 2005
Where J3396 sits
- 1J codesDrugs administered other than orally
- 2Active code J3396Injection, verteporfin, 0.1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3396 mean?
J3396 is the HCPCS code for “Injection, verteporfin, 0.1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3396?
CMS lists J3396’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3396
All J codesJ3387Injection, elivaldogene autotemcel, per treatmentJ3389Topical administration, prademagene zamikeracel, per treatmentJ3391Injection, atidarsagene autotemcel, per treatmentJ3392Injection, exagamglogene autotemcel, per treatmentJ3393Injection, betibeglogene autotemcel, per treatmentJ3394Injection, lovotibeglogene autotemcel, per treatmentJ3397Injection, vestronidase alfa-vjbk, 1 mgJ3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomesJ3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomesJ3400Injection, triflupromazine hcl, up to 20 mgJ3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 mlJ3402Injection, remestemcel-l-rknd, per therapeutic dose